Brexpiprazole (Rexulti)
Small molecule
Also known as OPC-34712
Evidence outlook
Approved: Major Depressive Disorder, Schizophrenia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (4)
- Treatment of agitation associated with dementia due to Alzheimer's disease
- Rxulti is indicated for the treatment of schizophrenia in adult and adolescents aged 13 years and older.
- Treatment of schizophrenia
- REXULTI (brexpiprazole) is indicated for: • treatment of schizophrenia in adults. In clinical trials, REXULTI was found to significantly improve both positive and negative symptoms. • use as an adjunct to antidepressants for the treatment of major depressive disorder (MDD) in adult patients with an inadequate response to prior antidepressant treatments during the current episode (see 14.1 Clinical Trials by Indication, Adjunctive Treatment in Major Depressive Disorder (MDD). • symptomatic management of agitation associated with Alzheimer’s dementia (AAD) in patients with aggressive...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
BEACON NCT01393613 · Acute Schizophrenia This was a randomized, quadruple-blind, placebo-controlled trial in 674 patients with acute schizophrenia, using a validated symptom-severity scale (PANSS) as the primary measure. The pooled comparison of the two higher doses against placebo reached statistical significance (p=0.0093), and the 4 mg dose was significant on its own (p=0.0022), but the 1 mg and 2 mg doses individually did not separate from placebo, so the result was only partially met. Registry: NCT01393613 | 3 | Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score. (Baseline, Weeks 1, 2, 3, 4, 5, and 6) 2014-02 | Change in PANSS total score at Week 6 vs placebo (primary endpoint): brexpiprazole 4 mg treatment difference -6.47 (p=0.0022); 1 mg and 2 mg doses showed numerical improvement but were not statistically significant (p>0.05). | Partial signal | link ↗ |
View 4 more trials
VECTOR NCT01396421 · Acute Schizophrenia Randomized, quadruple-blind, placebo-controlled trial in 636 patients with acute schizophrenia. The primary analysis, comparing brexpiprazole 2mg and 4mg doses to placebo on change in PANSS total score, showed a statistically significant improvement, with both doses individually beating placebo as well. Registry: NCT01396421 | 3 | Mean Change From Baseline to Week 6 Positive and Negative Syndrome Scale (PANSS) Total Score. 2014-01 | Change in PANSS total score at Week 6 vs placebo: brexpiprazole 2 mg treatment difference -8.72; 4 mg treatment difference -7.64 (both statistically significant). | Reliable signal | link ↗ |
NCT03238326 NCT03238326 · Schizophrenia This open-label follow-on study continued participants from an earlier randomized, blinded trial in adolescent schizophrenia to track long-term safety on brexpiprazole. With no control arm, it does not add new evidence of efficacy, but it does add long-term tolerability data on top of the earlier randomized result. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events (AEs)" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT03238326 | 3 | Number of Participants With Adverse Events (AEs) (From the first dose of study drug (including the conversion period and the open-label treatment period in the current study) up to 21 days after the last dose of study drug (up to approximately 25.6 months).); Number of Participants With Serious Treatment Emergent Adverse Events (TEAEs) (From the first dose of study drug (including the conversion period and the open-label treatment period in the current study) up to 21 days after the last dose of study drug (up to approximately 25.6 months).); Number of Participants Who Discontinued the Trial Due to AEs (From the first dose of study drug (including the conversion period and the open-label treatment period in the current study) up to 21 days after the last dose of study drug (up to approximately 25.6 months).) 2025-04-22 | Primary safety/tolerability outcome (this was an open-label, single-arm safety study, not an efficacy trial): treatment-emergent adverse events in 95/167 patients (56.9%); serious TEAEs in 5 patients (3.0%); discontinuation due to AEs in 2 patients (1.2%) | Weak signal | link ↗ |
NCT03198078 NCT03198078 · Schizophrenia Randomized, quadruple-blind trial with both a placebo and an active-comparator arm in 316 adolescents with schizophrenia. Brexpiprazole significantly reduced psychotic symptom severity versus placebo on the primary scale. Registry: NCT03198078 | 3 | Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score 2023-04-03 | Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014 | Reliable signal | link ↗ |
EQUATOR NCT01668797 · Schizophrenia The maintenance phase randomized 202 participants to brexpiprazole or placebo in a quadruple-blind design, and its clinical relapse endpoint was met in favor of brexpiprazole (hazard ratio 0.292, 95% CI 0.156–0.548; p<0.0001). The record provided does not report a primary-endpoint power or sample-size calculation, so the trial cannot be treated as adequately powered under the available documentation despite its otherwise strong design. Registry: NCT01668797 | 3 | Time From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse in Phase C. (From randomization to time of exacerbation of psychotic symptoms/impending relapse - up to 52 weeks) 2015-01 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (49)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
Other Dopamine D2/D3 and serotonin 5-HT1A receptor drugs
Aripiprazole (Abilify Maintena), Aripiprazole (Abilify), Aripiprazole lauroxil (Aristada Initio), Aripiprazole lauroxil (Aristada), Brexpiprazole long-acting injection (Kelun). Compare all 6 Dopamine D2/D3 and serotonin 5-HT1A receptor drugs
5 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Alzheimer's Disease: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Brexpiprazole (Rexulti): this drug | Phase 3 | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | Partial signal | NCT01862640: Change in CMAI Total score from baseline to Week 12 vs placebo (Study 1 = NCT01862640): brexpiprazole 2mg/day adjusted mean difference -3.77 (95% CI -7.38 to -0.17), p=0.040; brexpiprazole 1mg/day 0.23 (95% CI -3.40 to 3.86), p=0.90 NCT03620981: Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing. (Baseline and 10 weeks first dose, on average 10 weeks): Brexpiprazole 1 mg -11.7 units on a scale (Standard Error 1.2) | Brexpiprazole 2 mg -15.2 units on a scale (Standard Error 1.05) vs Placebo -8 units on a scale (Standard Error 1.03) | |
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | not yet graded | No reviewed efficacy summary in this indication | |
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | NCT05108922: Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab (6 Months): Donanemab 37.9% (95% CI 26.2 to 49.6) vs Aducanumab 1.6% (95% CI 0 to 4.6) | |
| Donepezil (Aricept) | Approved | Small molecule | Acetylcholinesterase | Partial signal | NCT00630851: Primary endpoint, SIB change at 6 months: mean difference 5.9 points vs placebo, statistically significant (ARICEPT label, Swedish 6-month study, 248 randomized). | |
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | NCT01767311: ADCOMS change from baseline at Month 12 (lower = less decline): lecanemab 10 mg/kg biweekly 0.077 and 10 mg/kg monthly 0.084 vs placebo 0.113; lower doses did not separate: 2.5 mg/kg biweekly 0.134, 5 mg/kg monthly 0.119, 5 mg/kg biweekly 0.116. missed | |
| AR1001 | Phase 3 | Small molecule | PDE5 | Partial signal | NCT03625622: Primary (ADAS-Cog-13 at Week 26): no significant differences between treatment groups in the overall population; post-hoc monotherapy subgroup on AR1001 30 mg improved 4.019 points (p=0.012). missed | |
| Bezisterim | Phase 3 | Small molecule | ERK/NF-kB inflammatory | Partial signal | No reviewed efficacy summary in this indication | |
| Buntanetap | Phase 3 | Small molecule | APP/tau/alpha-synuclein/TDP-43 (translation) | Partial signal | NCT05686044: ADAS-Cog11 change at Week 12: -2.32 placebo vs -1.34 (7.5 mg), -3.01 (15 mg), and -2.24 (30 mg) buntanetap/Posiphen; ADCS-CGIC at Week 12: 3.58 placebo vs 3.96 (7.5 mg), 3.61 (15 mg), and 3.83 (30 mg). | |
| Hydromethylthionine Mesylate | Phase 3 | Small molecule | Tau aggregation; Acetylcholine | Partial signal | NCT03446001: Change From Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) (16 mg/Day vs Control) (52 weeks): TRx0237 16 mg/Day 1.34 score on a scale (95% CI 0.32 to 2.36) vs Control 1.71 score on a scale (95% CI 0.69 to 2.73) NCT01689233: As-randomized primary comparison (100 mg vs 4 mg twice daily, the trial's pre-specified design): no significant difference on primary or secondary outcomes. Post-hoc modified-primary-outcome monotherapy cohort analysis: ADAS-cog effect size -3.14 (95% CI -5.32 to -0.97, p=0.0047) for 100 mg monotherapy (n=76) vs 4 mg as-randomized (n=388); -4.22 (95% CI -6.19 to -2.24, p<0.0001) for 4 mg monotherapy (n=79) vs 4 mg add-on (n=309) | |
| Masitinib | Phase 3 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | Partial signal | NCT01872598: Co-primary endpoints at week 24, masitinib 4.5 mg/kg/day vs placebo, each tested at 2.5%: ADAS-cog difference -2.15 (97.5% CI -3.48 to -0.81), p<0.001 (met); ADCS-ADL difference +1.82 (97.5% CI -0.15 to 3.79), p=0.038 (not met at the 2.5% level) | |
| Masupirdine | Phase 3 | Small molecule | Serotonin 5-HT6 receptor | Partial signal | NCT02580305: ADAS-Cog 11 change from baseline at Week 26: placebo +2.6 (SE 0.5); masupirdine 50 mg +2.0 (SE 0.5), difference vs placebo -0.5 (95% CI -1.8, 0.7; P=.41); masupirdine 100 mg +2.5 (SE 0.5), difference vs placebo -0.1 (95% CI -1.4, 1.2; P=.90) missed | |
| MLC901 (NeuroAiD II) | Phase 3 | Botanical | Traditional Chinese medicine (multi-component) | not yet graded | No reviewed efficacy summary in this indication | |
| Remlifanserin | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Remternetug | Phase 3 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | No reviewed efficacy summary in this indication | |
| Sodium Oligomannate | Phase 3 | Small molecule | Gut microbiome / neuroinflammation | Reliable signal | NCT02293915: Change in ADAS-cog12 from baseline to Week 36 (GV-971 minus placebo): -2.15 points (95% CI -3.07 to -1.23; p<0.0001; Cohen's d 0.53), favoring GV-971 | |
| Tertomotide | Phase 3 | Peptide | Telomerase (hTERT) | Partial signal | NCT05189210: 52주 차 ADAS-cog11의 최소제곱평균값 변화량은 GV1001 0.56mg과 1.12mg 투약군에서 각각 4.14점, 4.31점으로 위약군 4.30점 (LS-mean change in ADAS-cog11 at week 52: GV1001 0.56 mg 4.14 points, 1.12 mg 4.31 points, placebo 4.30 points; not statistically significant) missed | |
| Tricaprilin | Phase 3 | Small molecule | Ketone-body metabolism | Partial signal | NCT01741194: Change from baseline at 26 weeks, ADAS-Cog11 (APOE4 non-carriers): placebo (n=138) 0.0 vs AC-1204/tricaprilin (n=137) 0.6; LS mean difference -0.761, p=0.2458 (not significant) missed | |
| Trontinemab | Phase 3 | Multispecific antibody | Amyloid-beta (monoclonal antibody) | not yet graded | No reviewed efficacy summary in this indication | |
| Xanomeline / Trospium Chloride (Cobenfy) | Phase 3 | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | not yet graded | No reviewed efficacy summary in this indication | |
| AGB101 | Phase 2/3 | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A), low-dose | Partial signal | NCT03486938: CDR-SB difference vs placebo -0.10 (95% CI -0.85 to 0.58), not significant missed | |
| Blarcamesine | Phase 2/3 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) | Partial signal | NCT03790709: Co-primary endpoints at 48 weeks: ADAS-Cog13 difference vs placebo -2.027 (95% CI -3.522 to -0.533; P = 0.008); ADCS-ADL difference 0.775 (95% CI -0.874 to 2.423; P = 0.357, not significant). missed | |
| Deramciclane | Phase 2/3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Deraphan | Phase 2/3 | Small molecule | NMDA receptor / 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Emestedastat (Xanamem) | Phase 2/3 | Small molecule | 11-beta-HSD1 | Partial signal | NCT02727699: ADAS-Cog v14 (Baseline, Week 12): Xanamem™ -1.5 units on a scale (Standard Deviation 6.47) vs Placebo -0.7 units on a scale (Standard Deviation 6.65) | |
| Etalanetug | Phase 2/3 | Monoclonal antibody | Tau (monoclonal antibody) | Weak signal | Featured results are safety only in this race | |
| Nivegacetor | Phase 2/3 | Undisclosed | Gamma-secretase (modulator) | not yet graded | No reviewed efficacy summary in this indication | |
| PM012 | Phase 2/3 | Botanical | Traditional Chinese medicine (multi-component) | Partial signal | No reviewed efficacy summary in this indication | |
| T3D-959 | Phase 2/3 | Small molecule | PPAR delta/gamma | Partial signal | No reviewed efficacy summary in this indication | |
| 50561 | Phase 2 | Small molecule | RAC1 | Partial signal | No reviewed efficacy summary in this indication | |
| AADvac1 | Phase 2 | Vaccine | Tau | Weak signal | Featured results are safety only in this race | |
| ABvac40 | Phase 2 | Vaccine | Amyloid-beta (Aβx-40) | Partial signal | Featured results are non-efficacy and safety only in this race | |
| ACI-35.030 | Phase 2 | Vaccine | Tau | Partial signal | Featured results are safety only in this race | |
| AD04 | Phase 2 | Vaccine | Aluminium hydroxide (Alhydrogel) | not yet graded | No reviewed efficacy summary in this indication | |
| AstroStem | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | Weak signal | NCT03117738: ADAS-Cog change at Week 30: 5.9 (SD 6.8) AstroStem vs 3.0 (SD 5.4) placebo; n=7 vs 7. | |
| AV-1959R | Phase 2 | Vaccine | Amyloid-beta | Weak signal | Featured results are safety only in this race | |
| Bepranemab | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | Partial signal | NCT04867616: Primary endpoint, change in CDR-SB total score at Week 80: no benefit of low- or high-dose bepranemab over placebo in the overall study population (per UCB; no figures or p-value released). Key secondary outcomes favoured bepranemab: tau accumulation slowed by 33% to 58% and ADAS-Cog14 decline by 21% to 25% vs placebo. missed | |
| Betovumeline / Fesoterodine (ML-007C-MA) | Phase 2 | Small molecule | Muscarinic M1 and M4 receptors (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| BEY2153 | Phase 2 | Small molecule | APP/tau (translation) | Partial signal | No reviewed efficacy summary in this indication | |
| Cerebrolysin | Phase 2 | Peptide | Porcine brain-derived neuropeptide mixture (multi-target) | Partial signal | NCT00911807: Week 28 ADAS-COG+ change: -2.348 Cerebrolysin + donepezil, -1.711 Cerebrolysin, and -1.246 donepezil; overall p=0.6348. Cerebrolysin + donepezil vs donepezil: mean difference -1.080 (95% CI -3.324 to 1.163; p=0.3434). missed | |
| Deulumateperone | Phase 2 | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Diranersen | Phase 2 | RNA / oligonucleotide | MAPT mRNA (RNAi/ASO) | Weak signal | NCT05399888: Diranersen/BIIB080 (NCT05399888), Phase 2 CELIA study: primary endpoint (dose-response on CDR-SB change from baseline at Week 76) not met. missed | |
| Edaravone (TTYP01) | Phase 2 | Small molecule | oxidative stress | not yet graded | No reviewed efficacy summary in this indication | |
| Enrupatinib | Phase 2 | Small molecule | CSF-1R | not yet graded | No reviewed efficacy summary in this indication | |
| HT-4253 | Phase 2 | Small molecule | LRRK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Laromestrocel (Lomecel-B) | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | Weak signal | Featured results are safety only in this race | |
| Lemborexant (Dayvigo) | Phase 2 | Small molecule | Orexin receptor (repositioned) | Partial signal | NCT03001557: 4-week actigraphy endpoints vs placebo: L5 (restlessness measure) significantly decreased at 2.5mg, 5mg and 15mg doses (all p<0.05); relative amplitude significantly improved at 5mg and 15mg (both p<0.05); mean duration of sleep bouts significantly improved at 5mg (p<0.01) and 15mg (p=0.002). | |
| Leronlimab | Phase 2 | Monoclonal antibody | CCR5 co-receptor | not yet graded | No reviewed efficacy summary in this indication | |
| LHP588 | Phase 2 | Small molecule | Gingipain | not yet graded | No reviewed efficacy summary in this indication | |
| Lifonebart (VHB937) | Phase 2 | Monoclonal antibody | TREM2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mivelsiran | Phase 2 | RNA / oligonucleotide | APP mRNA (RNAi) | not yet graded | No reviewed efficacy summary in this indication | |
| MK-2214 | Phase 2 | Monoclonal antibody | Phospho-tau (pSer413) | Partial signal | Featured results are safety only in this race | |
| Moponetug | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | not yet graded | No reviewed efficacy summary in this indication | |
| NTRX-07 | Phase 2 | Small molecule | CB2 receptor | Weak signal | Featured results are safety only in this race | |
| ONO-2020 | Phase 2 | Small molecule | Epigenetic regulation (target undisclosed) | not yet graded | No reviewed efficacy summary in this indication | |
| Pegipanermin | Phase 2 | Biologic (subtype unspecified) | Soluble TNF (selective) | Partial signal | NCT05318976: Change in Early and Mild Alzheimer's Cognitive Composite (EMACC) (24 Weeks): 1.0 mg/kg XPro1595 0.05 z-score (Standard Error 0.04) vs 1.0 mg/kg Placebo 0.07 z-score (Standard Error 0.05) missed | |
| PRI-002 | Phase 2 | Small molecule | Amyloid-beta-42 oligomerization | Partial signal | No reviewed efficacy summary in this indication | |
| RB-ADSC | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| RO7269162 | Phase 2 | Small molecule | Gamma-secretase | not yet graded | No reviewed efficacy summary in this indication | |
| SAR448851 | Phase 2 | Small molecule | TREM2 | Weak signal | Featured results are safety only in this race | |
| Seltorexant | Phase 2 | Small molecule | Orexin-2 receptor (OX2R) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1707 | Phase 2 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | No reviewed efficacy summary in this indication | |
| Tazbentetol (SPG302) | Phase 2 | Small molecule | Dendritic spine density | not yet graded | No reviewed efficacy summary in this indication | |
| Emraclidine | Phase 1 | Small molecule | Muscarinic M4 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| LY03017 | Phase 1 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/5-HT2C, 5-HT2A/2C receptor | Weak signal | No reviewed efficacy summary in this indication | |
| LY03020 | Phase 1 | Small molecule | 5-HT2C/TAAR1 receptor | Weak signal | No reviewed efficacy summary in this indication |
Large race: only the 64 furthest-along competitors are listed; 58 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Brexpiprazole (Rexulti) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.